Jazz Pharmaceuticals Plc: Q2 2026 Financial Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026, for Jazz Pharmaceuticals Plc, a global biopharmaceutical company focused on rare diseases. The company operates in one business segment: the identification, development, and commercialization of pharmaceutical products for rare epilepsies, cancers, and sleep disorders. Key portfolio products include Xywav (sleep), Epidiolex (epilepsy), and an expanding oncology portfolio including Ziihera, Modeyso, and Zepzelca.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Total Revenues | $1,208.3 | $1,045.7 | $2,277.2 | $1,943.5 |
| Net Income (Loss) | $192.8 | $(718.5) | $485.9 | $(811.0) |
| Diluted EPS | $2.78 | $(11.74) | $7.17 | $(13.28) |
| Operating Cash Flow (6mo) | $823.9 (2026) vs $518.6 (2025) | |||
| Cash & Investments | $2,199.8 (as of June 30, 2026) | |||
| Total Debt (Principal) | $4,395.0 (as of June 30, 2026) | |||
| Gross Margin | 90.4% | 88.9% | 89.0% | 88.6% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 16% in Q2 2026 and 17% for the six months ended June 30, 2026, compared to the prior year. This was driven by volume growth in Xywav (+12%), Epidiolex (+12%), and Zepzelca (+42% in Q2), as well as the commercial launch of Modeyso ($48.2M in Q2) and Ziihera.
- Profitability Turnaround: The company reported a net income of $192.8 million in Q2 2026, a significant improvement from a net loss of $718.5 million in Q2 2025. The prior year loss was heavily impacted by a $905.4 million charge for acquired in-process research and development (IPR&D) related to the Chimerix Acquisition.
- One-Time Gains: The six-month 2026 results included a $122.8 million pre-tax gain from the sale of a Priority Review Voucher (PRV) in January 2026.
- Debt Reduction: In June 2026, the company repaid the $1.0 billion aggregate principal amount of its 2026 Notes at maturity. Additionally, the 2030 Notes ($1.0 billion) were reclassified to current liabilities because the share price condition for exchangeability was met during the quarter.
- Acquisition Activity: The company incurred $77.0 million in acquired IPR&D expenses in Q2 2026, related to new collaborations with AbCellera ($56.0M) and an asset purchase from Werewolf ($21.0M).
Guidance, Outlook, and Risks
- Outlook: Management expects total revenues in 2026 to increase compared to 2025, driven by growth in Xywav, Epidiolex, and oncology products. This is expected to be offset by a reduction in royalty revenues from high-sodium oxybate authorized generics and declining Xyrem revenues due to generic competition.
- Regulatory Milestones:
- Ziihera: An sBLA for first-line HER2-positive gastroesophageal adenocarcinoma (GEA) is under Priority Review with a PDUFA date of August 25, 2026.
- Zepzelca: Following negative results in the LAGOON trial for second-line SCLC, the company plans to submit a labeling supplement in Q3 2026 to remove the second-line indication, while maintaining the first-line maintenance indication.
- Modeyso: Continued approval is contingent on the Phase 3 ACTION confirmatory trial.
- Key Risks:
- Generic Competition: Significant competition for Xywav and Xyrem from authorized generics (AG) and generic high-sodium oxybate products (e.g., from Amneal, Ascent, Hikma). Patent litigation with Lupin and Teva regarding Xywav remains ongoing.
- Debt Exchangeability: The 2030 Notes are currently exchangeable at the option of holders. While none have been exchanged as of the filing date, the company may need to settle exchanges using cash or borrowings.
- Regulatory Scrutiny: Accelerated approvals for oncology products (Ziihera, Modeyso) require successful completion of confirmatory trials to maintain market authorization.
Investor Verification Checklist
- Debt Structure: Verify the status of the $1.0 billion 2030 Notes exchangeability and the company's liquidity plan to settle potential exchanges.
- Patent Litigation: Monitor the consolidated patent infringement lawsuits against Lupin and Teva regarding Xywav, as a loss could accelerate generic entry.
- Oncology Confirmatory Trials: Track the progress of the Phase 3 ACTION trial for Modeyso and the Phase 3 HERIZON-BTC-302 trial for Ziihera, as failure could result in withdrawal of accelerated approvals.
- Generic Impact: Assess the actual market share erosion of Xywav and Xyrem due to the launch of generic high-sodium oxybate products by Amneal and Ascent in Q1 2026.
- PRV Proceeds: Confirm the utilization of the $200 million cash proceeds from the PRV sale (net of payments to former Oncoceutics stockholders).